Phase II AK Study in Organ Transplant Patients

Inclusion Criteria: * Organ transplant recipients with stable transplant function and who received their transplant at least 2 years prior to study entry * Organ transplant patients who have had at least one biopsy-positive SCC * Aged 18 - 75 years * Written informed consent to the performance of all study-specific procedures Exclusion Criteria: * Allergy to afamelanotide (CUV1647) or the polymer contained in the implant * History of melanoma * Current pigmentary disorders such as melasma * Diagnosed with HIV/AIDS, or hepatitis B or C * Current history of drug or alcohol abuse (in the last 12 months) * Clinically significant organ dysfunction, history of medical disorders or other factors, which in the opinion of the investigator will interfere with the interpretation of study outcome measures * Major medical or psychiatric illness * Pregnancy as confirmed by positive serum beta-HCG pregnancy test prior to baseline or lactating mothers * Females of child bearing potential not using adequate contraceptive measures * Participation in a clinical trial for an investigational agent within 30 days prior to the screening visit * Use of regular medications or any other factors that may affect skin pigmentation Discontinuation Criteria: * Initiation of treatment with systemic retinoids * Change of class of systemic immunosuppressant treatment